The introduction of tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). Imatinib mesylate, which competitively targets the adenosine 5-triphosphate (ATP)-...
No takes yet. Share an insight, caveat, or question.
Markose et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: